The Association of Urinary Sclerostin and Renal Magnesium Handling in Type 2 Diabetic Patients with Chronic Kidney Disease

被引:3
|
作者
Wu, Ching-Fang [1 ,2 ]
Liou, Hung-Hsiang [3 ,4 ]
Kuo, Chin-Chi [5 ,6 ]
Tsai, Ming-Hsien [7 ]
Chang, Min-Yu [1 ,4 ]
Lee, Yi-Che [1 ,8 ]
Lin, Tsun-Mei [9 ,10 ]
Hung, Shih-Yuan [1 ,4 ]
机构
[1] I Shou Univ, Coll Med, Sch Med, Kaohsiung, Taiwan
[2] E Da Canc Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[3] Hsin Jen Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan
[4] E Da Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[5] China Med Univ, China Med Univ Hosp, Big Data Ctr, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan
[7] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan
[8] E Da Dachang Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[9] I Shou Univ, Dept Med Lab Sci, Kaohsiung, Taiwan
[10] E Da Hosp, Dept Med Res, Kaohsiung, Taiwan
关键词
Chronic kidney disease; Sclerostin; Fractional excretion of calcium; Fractional excretion of magnesium; Type 2 diabetes mellitus; METABOLISM; CALCIUM;
D O I
10.1159/000516844
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: Sclerostin could enhance renal excretion of calcium (Ca) and phosphate (P). The association between sclerostin and magnesium (Mg) has not yet discovered. In patients with type 2 diabetes mellitus (T2DM) or chronic kidney disease (CKD), higher serum sclerostin and altered renal excretion of Ca, P, and Mg were detected. Therefore, we tried to evaluate if there was any association between sclerostin and fractional excretion of Ca, P, and Mg (FeCa, FeP, and FeMg) in T2DM with CKD. Methods: In this prospective cohort study, 43 T2DM patients without CKD or with CKD stage 1-5 were enrolled. Values of parameters, including serum and urine sclerostin, were collected at baseline and 6 months later. For baseline data, the Mann-Whitney U test, chi(2) test, or Spearman's correlation were used. For multivariate repeated measurement analysis, generalized estimating equation (GEE) model was utilized. Results: Patients with lower estimated glomerular filtration rate had higher serum sclerostin, FeP, FeMg, and lower FeCa. By correlation analysis, serum sclerostin was negatively associated with FeCa (p = 0.02) and positively associated with FeP (p = 0.002). The urine sclerostin to creatinine ratio (Uscl/Ucre) was positively correlated with FeP (p = 0.007) and FeMg (p = 0.005). After multivariate analyses by GEE model, serum sclerostin was still inversely associated with FeCa, while Uscl/Ucre was significantly associated with FeMg. On the other hand, FeP lost its associations with serum sclerostin or Uscl/Ucre. Conclusion: In our study population of T2DM patients with or without CKD, the inverse correlation between serum sclerostin and FeCa could not be explained by the calciuric effect of sclerostin. In addition, a newly discovered positive association between urinary sclerostin and FeMg indicated a possible role of urinary sclerostin in regulating renal Mg handling especially over distal convoluted tubules.
引用
收藏
页码:514 / 522
页数:9
相关论文
共 50 条
  • [21] Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
    Nogueira, Claudia
    Souto, Selma B.
    Vinha, Eduardo
    Carvalho-Braga, Daniel
    Carvalho, Davide
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 12 (04): : 483 - 494
  • [22] Clinical assessment of phosphorus status, balance and renal handling in normal individuals and in patients with chronic kidney disease
    Huang, Chou-Long
    Moe, Orson W.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (04) : 452 - 458
  • [23] Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease
    Li, Qiuhong
    Wang, Tongdan
    Shao, Xian
    Fan, Xiaoguang
    Lin, Yao
    Cui, Zhuang
    Liu, Hongyan
    Zhou, Saijun
    Yu, Pei
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [24] Cystatin C and collagen type IV in diagnostics of chronic kidney disease in type 2 diabetic patients
    Klimontov, V. V.
    Eremenko, N. V.
    Myakina, N. E.
    Fazullina, O. N.
    DIABETES MELLITUS, 2015, 18 (01): : 87 - 93
  • [25] Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Rizk, Dana, V
    Silva, Arnold L.
    Pergola, Pablo E.
    Toto, Robert
    Warnock, David G.
    Chin, Melanie P.
    Goldsberry, Angie
    O'Gradye, Megan
    Meyere, Colin J.
    McCullough, Peter A.
    CARDIORENAL MEDICINE, 2019, 9 (05) : 316 - 325
  • [26] Association of urinary calcium and phosphorus excretion with renal disease progression in type 2 diabetes
    Duan, Suyan
    Sun, Lianqin
    Zhu, Huanhuan
    Nie, Guangyan
    Zhang, Chengning
    Huang, Zhimin
    Zhang, Bo
    Xing, Changying
    Yuan, Yanggang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 178
  • [27] Renal potassium handling in chronic kidney disease: Differences between patients with or wihtout hyperkalemia
    Caravaca-Fontan, Fernando
    Valladares, Julian
    Diaz-Campillejo, Rosa
    Barroso, Sergio
    Luna, Enrique
    Caravaca, Francisco
    NEFROLOGIA, 2020, 40 (02): : 152 - 159
  • [28] Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?
    Andreja Figurek
    Goce Spasovski
    International Urology and Nephrology, 2018, 50 : 1863 - 1870
  • [29] Renal Function following Fluorescein Angiography in Diabetic Patients with Chronic Kidney Disease
    Ebrahimiadib, Nazanin
    Mirzaei, Shaghayegh Hadavand
    Riazi-Esfahani, Hamid
    Amini, Manouchehr
    JOURNAL OF OPHTHALMIC & VISION RESEARCH, 2023, 18 (02) : 170 - 174
  • [30] Association between Urinary Creatinine Excretion and Hypothyroidism in Patients with Chronic Kidney Disease
    Matsuoka-Uchiyama, Natsumi
    Tsuji, Kenji
    Takahashi, Kensaku
    Fukushima, Kazuhiko
    Takeuchi, Hidemi
    Kitamura, Shinji
    Inagaki, Kenichi
    Uchida, Haruhito A. A.
    Wada, Jun
    DIAGNOSTICS, 2023, 13 (04)